Importance of Low- and Moderate-Grade Adverse Events in Patients' Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 Trial.

MLA

O’Connell, Nathaniel S., et al. “Importance of Low- and Moderate-Grade Adverse Events in Patients’ Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 Trial.” Journal of Clinical Oncology, vol. 42, no. 3, Jan. 2024, pp. 266–72. EBSCOhost, https://doi.org/10.1200/JCO.23.00377.

APA

O’Connell, N. S., Zhao, F., Lee, J.-W., Ip, E. H., Peipert, J. D., Graham, N., Smith, M. L., Gareen, I. F., Carlos, R. C., Obeng-Gyasi, S., Sparano, J. A., Shanafelt, T. D., Thomas, M. L., Cella, D., Wagner, L. I., & Gray, R. (2024). Importance of Low- and Moderate-Grade Adverse Events in Patients’ Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 Trial. Journal of Clinical Oncology, 42(3), 266–272. https://doi.org/10.1200/JCO.23.00377

Chicago

O’Connell, Nathaniel S., Fengmin Zhao, Ju-Whei Lee, Edward H. Ip, John Devin Peipert, Noah Graham, Mary Lou Smith, et al. 2024. “Importance of Low- and Moderate-Grade Adverse Events in Patients’ Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 Trial.” Journal of Clinical Oncology 42 (3): 266–72. doi:10.1200/JCO.23.00377.